Ignacio I. Wistuba, M.D., is Professor and Chair of the Department of Translational Molecular Pathology, Division of Pathology & Laboratory Medicine, M.D. Anderson Cancer Center at Houston, Texas, United States. He is also Professor of Thoracic/Head and Neck Medical Oncology and Director of the Thoracic Molecular Pathology Laboratory. Dr. Wistuba earned his medical degree in 1985 from the Austral University of Chile in Valdivia and trained in surgical pathology in the Catholic University of Chile in Santiago. He furthered his training in the United States at The University of Texas Southwestern Medical Center as a postdoctoral fellow in lung cancer molecular pathology research at the Hamon Center for Therapeutic Oncology Research Center. In 2003, he joined MD Anderson as Associate Professor of Pathology and Thoracic/Head and Neck Medical Oncology. In 2008 he was promoted to Professor, in 2010 was named the Jay and Lori Eisenberg Professor, and in 2013 named Anderson Clinical Faculty Chair for Cancer Treatment and Research. Dr. Wistuba is a specialist in lung cancer surgical and molecular pathology. He has a strong record of scientific achievement in the study of lung cancer, which includes more than 300 peer-reviewed papers and several book chapters. His research interests include the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer, and the identification of novel molecular targets and validation of biomarkers for targeted therapy. His research is funded by grants from NIH/NCI, Cancer Prevention Research Institute of Texas (CPRIT), V Foundation and the U.S. Department of Defense in addition to research agreements with pharmaceutical and biotechnology companies. Dr. Wistuba oversees biomarker studies for lung cancer therapeutic clinical trials, including the MD Anderson BATTLE program, and he is leader of the MD Anderson Cancer Center Support Grant (CCSG) Tissue Biorepository and Pathology Resources (TBPR). He currently serves as the pathologist of the Lung Cancer Committee for the Southwestern Oncology Group (SWOG), the Lung Cancer Mutation Consortium (LCMC), and member of the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC). He is also member of the American Association of Oncology (ASCO) Research Committee. He serves as senior editor of Cancer Prevention Research and on the Editorial Boards of Clinical Cancer Research, Annals of Diagnostic Pathology, Archives of Pathology and Laboratory Medicine, and the Journal of Clinical Oncology.

 Oncology